$OPY

Oppenheimer maintained an 'Outperform' rating for Elastic (ESTC) and raised its price target to $118 from $100. The company's stock is currently trading at $97.81, which is 7.0% below its GF Value™ of $105.18, suggesting it is undervalued. Elastic has a GF Score™ of 81/100, indicating strong overall performance, particularly in growth and valuation. Five gurus hold positions in ESTC, with four adding to their stakes recently.

Oppenheimer Holdings stock rose 2.7% in pre-market trading to $123.25, surpassing its 52-week high, as the company distributed a $0.20 per share dividend. This follows strong Q2 2026 earnings, with revenue up 21.9% YoY to $454.9M and adjusted EPS at $4.27. Client assets under management reached a record $59.4B. The stock's technical breakout and positive fundamentals drove the gain, independent of broader market trends.

Oppenheimer maintained its Outperform rating for StepStone Group Inc (STEP) but lowered its price target from $90.00 to $88.00. The company's GF Value™ is $87.05, indicating it is 42.1% undervalued. StepStone operates in asset management with a market cap of $4.14 billion. Insider activity shows $5,022,000 in buys over the last three months. The GF Score™ is 51/100, reflecting moderate performance.

Oppenheimer maintained an 'Outperform' rating for Revolution Medicines (RVMD) and raised its price target from $230 to $260. The biotech company has a $46.8B market cap but faces profitability and growth concerns, with a GF Score of 25/100. Insiders have sold $54.5M in shares over the past three months.

Oppenheimer maintained its 'Outperform' rating for Okta Inc (OKTA) and raised its price target from $170 to $190, an 11.76% increase. Okta's stock is currently priced at $164.57, which is 57.3% overvalued compared to its GF Value™ of $104.62, according to GuruFocus. The company has a GF Score™ of 73/100, indicating fair performance relative to its peers. Insider activity shows significant selling, with $21,827,346 in insider sell value over the past three months.

Oppenheimer maintained an 'Outperform' rating for Hamilton Lane (HLNE) but lowered its price target from $182 to $181. The stock is seen as 37.9% undervalued with a GF Value of $174.92. Insider buying totaled $14.24M over the last 3 months. The company has a market cap of $4.71B and manages $986B in assets.

Oppenheimer maintained an 'Outperform' rating for Nutanix (NTNX) and raised its price target to $85 from $80. The stock is currently at $70.55, slightly overvalued according to GF Value™. Analysts are bullish, but insider selling and profitability concerns may give investors pause.

Oppenheimer maintained its 'Outperform' rating for Blackstone (BX) and raised its price target to $171 from $140, citing confidence in the company's performance. Blackstone's GF Value is $200.87, suggesting a 27.8% undervaluation. The company has a GF Score of 70, indicating solid investment potential, with strengths in growth and profitability.

Oppenheimer reduced its price target for Ridgepost Capital to $15 from $16 but maintained an Outperform rating. The company's stock has seen a 5-day change of 8.710 USD, a 1st Jan change of +0.23%, and a -11.21% year-to-date change.

Oppenheimer raised its price target for Affirm to $100 from $87 while maintaining an outperform rating, according to the company. Affirm's stock has seen a 3.95% increase over the past year, as reported.